Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
Ishikawa J, Matsumura I, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Matsuoka KI, Shibayama H, Hino M, Hirase C, Kamimura T, Shimose T, Akashi K, Kanakura Y. Ishikawa J, et al. Among authors: miyamoto t. Int J Hematol. 2018 May;107(5):535-540. doi: 10.1007/s12185-018-2401-y. Epub 2018 Jan 23. Int J Hematol. 2018. PMID: 29362980 Clinical Trial.
Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy.
Miyamura K, Miyamoto T, Tanimoto M, Yamamoto K, Kimura S, Kawaguchi T, Matsumura I, Hata T, Tsurumi H, Saito S, Hino M, Tadokoro S, Meguro K, Hyodo H, Yamamoto M, Kubo K, Tsukada J, Kondo M, Aoki M, Okada H, Yanada M, Ohyashiki K, Taniwaki M. Miyamura K, et al. Among authors: miyamoto t. Leuk Res. 2016 Dec;51:11-18. doi: 10.1016/j.leukres.2016.09.009. Epub 2016 Sep 5. Leuk Res. 2016. PMID: 27771544 Clinical Trial.
Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).
Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y. Nagafuji K, et al. Among authors: miyamoto t. Int J Hematol. 2019 Dec;110(6):675-682. doi: 10.1007/s12185-019-02736-5. Epub 2019 Sep 19. Int J Hematol. 2019. PMID: 31538327 Clinical Trial.
Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
Takenaka K, Nagafuji K, Takase K, Kamimura T, Mori Y, Ito Y, Nishi Y, Henzan H, Kato K, Harada N, Eto T, Miyamoto T, Teshima T, Akashi K. Takenaka K, et al. Among authors: miyamoto t. Int J Hematol. 2012 Jul;96(1):94-100. doi: 10.1007/s12185-012-1087-9. Epub 2012 May 1. Int J Hematol. 2012. PMID: 22547196 Clinical Trial.
Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission.
Eto T, Takase K, Miyamoto T, Ohno Y, Kamimura T, Nagafuji K, Takamatsu Y, Teshima T, Gondo H, Taniguchi S, Akashi K, Harada M. Eto T, et al. Among authors: miyamoto t. Int J Hematol. 2013 Aug;98(2):186-96. doi: 10.1007/s12185-013-1378-9. Epub 2013 Jun 11. Int J Hematol. 2013. PMID: 23754766
Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma.
Miyamoto T, Yoshimoto G, Kamimura T, Muta T, Takashima S, Ito Y, Shiratsuchi M, Choi I, Kato K, Takenaka K, Iwasaki H, Takamatsu Y, Teshima T, Akashi K. Miyamoto T, et al. Int J Hematol. 2013 Sep;98(3):337-45. doi: 10.1007/s12185-013-1402-0. Epub 2013 Jul 23. Int J Hematol. 2013. PMID: 23877150 Clinical Trial.
4,197 results